1. At Novion Technologies, we are
Advancing Patient Protection Against Infection
by re-inventing how infections are treated and prevented.
Our Solution:
A family of novel antiseptics for wound dressings and
medical device coatings with minimal tissue toxicity, excellent
potency against pathogens, and little concern for resistance.
Preventing and Treating Infection
Contact Information
Spokane, WA
• David J. Vachon, CEO and President
• Email: djvachon@iasismolecular.com
• Phone: (509) 210-0736
• Website: www.noviontechnologies.com
Competitive Advantages:
0
100
200
300
400
500
600
Fibroblasts P. Aeruginosa S. Aureus
Concentration(µg/mL)
Commercial
AgNO3
SSD
Ag Zeolites
Ag NPs
Iodosorb® Gel
Silver-thiolates
SSG*
PSG
SG
*silver
sulfadiazine
reformulation
Cytocompatibility
(IC50)
Antimicrobial activity
(MIC90)
• Novion’s silver-thiolates have significantly improved
cytocompatibility (high IC50) versus the competition while
remaining potent against virulent pathogens
• Improved solubility relative to silver sulfadiazine, silver oxide, silver
nanoparticles and silver phosphate (diffusion-based release)
• Active at low concentrations (<20 μg/mL)
• Simple, green synthesis (all aqueous)
• IP protection for three clinically-viable novel compounds
• Compounds facilitate improved wound closure rates vs. controls
Protease inhibition, oxidative stress reduction & reduced toxicity
Performance, Cost, &
Implementation
Silver thiolates can be incorporated into a variety of different
materials, are color stable, shelf-stable, and are much less toxic
than ordinary silver
Polyurethane
hydrogels
Amorphous hydrogel
ointments
Polyurethane
foams
Silver-thiolates enable
improved healing in
polymicrobial infected burn
wounds (rat) relative to industry
standard silver sulfadiazine
(SSD) (accepted treatment).
Silver-Thiolates:
-10
0
10
20
30
40
50
60
70
80
90
100
0 2 4 6 8 10 12 14
PercentHealed
Days of Treatment
SGC Dressing
SSD (Estimated)
Blank Dressing
Ag
Ag Thiol
Thiol+
Ag S
0
200
400
600
800
1000
1200
1400
1600
1800
0.00 0.58 0.77
Concentraction(µg/mL)
GSH per Ag
Therapeutic Range (TR)
MRSA MIC90
Fibroblast IC50
TR
TR
TR
Increasing Thiol
Concentration
Ø
Pre-clinical (in vivo) studies
The addition of a thiol
(adjuvant) to a silver
compound greatly
enhances the
therapeutic range (TR)
of the silver antiseptic.
(see figure to the right)
• Small molecule silver-based antiseptics
• Improved solubility, nominal toxicity,
excellent potency
• Facile, single-step synthesis
• Readily prepared as topical ointments,
hydrocolloids, solid dressings, and as coatings
• Broadly bactericidal and fungicidal
For the disinfection, prevention of infection, and
treatment of infected wounds
Polyurethane foams loaded with a silver-thiolate prevent the growth
of gram-positive and gram-negative pathogens (Kirby-Bauer).
MRSAKlebsiella pneumoniae
Antimicrobial Countermeasures
for Medical Devices
Novion’s novel silver therapeutics are applicable to a variety of
advanced wound care devices as well as medical device coatings.
Infections are a Socioeconomic Burden
Deadly & CostlyThe Problem:
Wound Infections (diabetic ulcers, burns & chronic wounds)
• Infection (osteomyelitis) can lead to amputation
• Diabetic ulcers ~$13B in annual healthcare costs
• Large burns have high mortality rate (50-60%)
Healthcare-Associated Infections (HAIs)
• Kill 100K annually, $50B+ recurring problem (U.S.)
• Patients at risk: percutaneous devices & surgical sites
• All clinical surfaces harbor pathogens
The Threat of Superbugs
• Antibiotic resistance has severely
limited treatment options
• New & improved antibiotics and/or
antiseptic agents are needed
• U.S. GAIN Act created to promote
the development of new agents
• Our compounds are highly effective
against many resistant organisms
Many solutions are ineffective and toxic to human tissue –
resulting in recurring infections and slower wound healing.
Traction: Ready for Translation to the Clinic
• Non-Dilutive Funding – 6 federal*, 3 local
‐ NIH (NIGMS), DoD (CDMRP), and HSSA (Spokane)
• Broad IP landscape (5 pending, 1 issued)
• Academic collaborations (Virginia Commonwealth
University & Western University, Ontario, CA)
• Washington Innovation Network (WIN) mentorship
• Ignite Washington Accelerator Program member
*R43GM108378-01, R43GM109610-01A1, R43AI098214-01A1, R43GM103116-01,
R43DK085957-01, W81XWH-11-2-0117 (DoD)
1 cm 1 cm